FidoCure^® Veterinary Team Blog

FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024 

Our study in Nature's Scientific Reports was the 17th most downloaded cancer paper in 2023!

Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript "Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics," recently published in Scientific Reports.

In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.

Thank you to all the veterinary technicians who have helped us enroll over 4500 dogs on the FidoCure platform. We are so thankful for your partnership in fighting cancer on both ends of the leash! 

Enter below for your chance to win:

 

Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure provides targeted therapies that are transforming the landscape of canine cancer care.

FOR IMMEDIATE RELEASE